Literature DB >> 2559173

Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy.

S Feriozzi1, A Pierucci, E Roscia, G A Cinotti, G Pecci.   

Abstract

Ten hypertensive, non-nephrotic patients with immunoglobulin (IgA) nephropathy treated with conventional therapy (vasodilators, beta-blockers, diuretics) were observed for 21.4 +/- 9 months. Treatment was then changed to an angiotensin converting enzyme (ACE) inhibitor alone for an additional 22.6 +/- 9 months. The ACE inhibitor therapy was associated with a lower diastolic blood pressure and a slowing in the rate of decline in renal function, but no change in proteinuria.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559173     DOI: 10.1097/00004872-198909007-00015

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  4 in total

Review 1.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 2.  Treatment of IgA nephropathy.

Authors:  C Y Lin
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy.

Authors:  Norio Ieiri; Osamu Hotta; Toshinobu Sato; Yoshio Taguma
Journal:  Clin Exp Nephrol       Date:  2011-09-13       Impact factor: 2.801

4.  Comparative efficacy of different renin angiotensin system blockade therapies in patients with IgA nephropathy: a Bayesian network meta-analysis of 17 RCTs.

Authors:  Zhihao Huo; Huizhen Ye; Peiyi Ye; Guanqing Xiao; Zhe Zhang; Yaozhong Kong
Journal:  PeerJ       Date:  2021-07-06       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.